| Date Filed | Type | Description |
| 09/26/2023 |
8-K
| Investor presentation |
| 08/09/2023 |
8-K
| Quarterly results |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/07/2023 |
8-K
| Investor presentation |
| 07/24/2023 |
8-K
| Quarterly results |
| 05/04/2023 |
8-K
| Quarterly results |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/16/2023 |
4
| Smeal Tod (Chief Scientific Officer) has filed a Form 4 on Cardiff Oncology, Inc.|
Txns:
| Granted 167,088 options
@ $1.72, valued at
$287.4k
|
|
| 03/16/2023 |
4
| Levine James E. (CFO) has filed a Form 4 on Cardiff Oncology, Inc.|
Txns:
| Granted 197,472 options
@ $1.72, valued at
$339.7k
|
|
| 03/16/2023 |
4
| Kelemen Vicki (Exec. VP and COO) has filed a Form 4 on Cardiff Oncology, Inc.|
Txns:
| Granted 125,520 options
@ $1.72, valued at
$215.9k
|
|
| 03/16/2023 |
4
| Erlander Mark (CEO) has filed a Form 4 on Cardiff Oncology, Inc.|
Txns:
| Granted 482,064 options
@ $1.72, valued at
$829.2k
|
|
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/02/2023 |
8-K
| Quarterly results |
| 03/02/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/14/2023 |
SC 13G/A
| CAXTON CORP reports a 2.2% stake in Cardiff Oncology, Inc. |
| 02/09/2023 |
3
| Kabbinavar Fairooz (Chief Medical Officer) has filed a Form 3 on Cardiff Oncology, Inc. |
| 02/09/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/02/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/26/2023 |
SC 13G
| ACORN BIOVENTURES, L.P. reports a 6.4% stake in Cardiff Oncology, Inc. |
| 01/26/2023 |
SC 13D/A
| ACORN BIOVENTURES, L.P. reports a 6.4% stake in CARDIFF ONCOLOGY, INC. |
| 11/29/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/03/2022 |
8-K
| Quarterly results |
| 11/03/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/11/2022 |
4
| Armitage James O (Director) has filed a Form 4 on Cardiff Oncology, Inc.|
Txns:
| Bought 13,000 shares
@ $1.5564, valued at
$20.2k
|
|
| 10/03/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 09/20/2022 |
4
| White Lale (Director) has filed a Form 4 on Cardiff Oncology, Inc.|
Txns:
| Bought 15,000 shares
@ $1.635, valued at
$24.5k
|
|
| 09/19/2022 |
4
| TANNENBAUM RENEE P (Director) has filed a Form 4 on Cardiff Oncology, Inc.|
Txns:
| Bought 6,400 shares
@ $1.715, valued at
$11k
Bought 3,600 shares
@ $1.72, valued at
$6.2k
|
|
| 09/19/2022 |
4
| PACE GARY W (Director) has filed a Form 4 on Cardiff Oncology, Inc.|
Txns:
| Bought 150,000 shares
@ $1.71, valued at
$256.5k
|
|
| 09/19/2022 |
4
| Levine James E. (CFO) has filed a Form 4 on Cardiff Oncology, Inc.|
Txns:
| Bought 30,000 shares
@ $1.557, valued at
$46.7k
|
|
| 09/12/2022 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 09/06/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
|